These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 7716891

  • 1. [Results of induction therapy in newly diagnosed acute myeloid leukemias in study 911 at the Institute of Hematology and Blood Transfusion].
    Lemez P, Vítek A, Jelínek J, Lukásová M, Palecek A, Sajdová J, Jedlicková A, Vorlová Z.
    Vnitr Lek; 1995 Jan; 41(1):34-9. PubMed ID: 7716891
    [Abstract] [Full Text] [Related]

  • 2. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P, Vítek A, Michalová K, Zemanová Z, Lukásová M.
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [Abstract] [Full Text] [Related]

  • 3. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Mar; 82(5 Suppl):9-12. PubMed ID: 9402747
    [Abstract] [Full Text] [Related]

  • 4. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Mar; 82(6):660-3. PubMed ID: 9499664
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB.
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [Abstract] [Full Text] [Related]

  • 9. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 10. [Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
    Lemez P, Gáliková J, Haas T.
    Vnitr Lek; 1999 Jun; 45(6):342-6. PubMed ID: 11045169
    [Abstract] [Full Text] [Related]

  • 11. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.
    Cancer Res; 1998 Sep 15; 58(18):4173-9. PubMed ID: 9751631
    [Abstract] [Full Text] [Related]

  • 12. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
    Patterson D, Kravtsova VM, Petrova EM, Zabelina TS, Balaian LN.
    Ter Arkh; 1987 Sep 15; 59(12):81-6. PubMed ID: 3482131
    [Abstract] [Full Text] [Related]

  • 13. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 14. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.
    Srp Arh Celok Lek; 1995 Dec 15; 123(11-12):279-85. PubMed ID: 16296239
    [Abstract] [Full Text] [Related]

  • 15. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
    Al Bahar S, Pandita R, Bavishi K, Kreze O.
    Indian J Cancer; 2004 Dec 15; 41(3):125-8. PubMed ID: 15472411
    [Abstract] [Full Text] [Related]

  • 16. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 15; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 17. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
    Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W.
    Cancer; 1997 Jan 01; 79(1):59-68. PubMed ID: 8988727
    [Abstract] [Full Text] [Related]

  • 18. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y, Sampi K, Kuraishi Y, Okabe K, Tamura K, Mizoguchi H, Saito H, Masaoka T, Ogawa M.
    Int J Hematol; 1999 Jul 01; 70(1):20-5. PubMed ID: 10446490
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
    Lemez P, Urbánek V.
    Neoplasma; 2005 Jul 01; 52(5):398-401. PubMed ID: 16151584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.